Peer-Reviewed Publication
Ann Am Thorac Soc2026October 14, 2026Journal Article
Quantitative CT in the real-world evaluation of progressive pulmonary fibrosis; the REVISE PPF multicentre observational study.
Ayodeji Adegunsoye1, Anna J Podolanczuk2, Teja Kulkarni3, Christian Rennison-Jones4, Steven Rothenberg3, Kristin Berger2, Yana Rabkova2, Christine Wu2, Lydia Chelala5, Cathryn T Lee1, Iazsmin Bauer Ventura1, Mary E Strek1, Finja Ottink4, Wassim Bou-Zeid4, Olivier Joly4, Eric White6, George Wj Harston4,7, Claire Fernandez4, Anand Devaraj4,8,9, Peter M George4,8,9
1Department of Medicine, University of Chicago, Chicago, IL, United States.
2Department of Medicine, Weill Cornell Medical College, New York, NY, United States.
3The University of Alabama at Birmingham Heersink School of Medicine, Birmingham, Alabama, USA.
4Brainomix, Oxford UK.
5Department of Radiology, University of Chicago, Chicago, IL, United States.
6Boehringer Ingelheim Pharmaceuticals, Inc., Ridgefield, CT, United States.
7Oxford University Hospitals NHS Foundation Trust, UK.
8Royal Brompton Hospital London, UK.
9National Heart and Lung Institute, Imperial College London, UK.
Abstract
RATIONALE AND OBJECTIVE: We assessed whether an FDA-cleared quantitative CT (qCT) tool (Brainomix, e-Lung) identifies progressive pulmonary fibrosis (PPF) earlier than routine clinical diagnosis and evaluated the prognostic value of baseline and serial imaging biomarkers.
METHODS: Multicentre retrospective study involving University of Alabama (UAB), Weill Cornell Medicine (WCM) and University of…
Create a free account to keep reading
Free members get 10 full research views every month across publications, clinical trials, FDA clearances, adverse events, and NIH grants. No credit card required.
Want unlimited research access? See Pro plans